Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Int J Urol ; 22(4): 368-71, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25599801

RESUMO

OBJECTIVE: To evaluate the long-term results of laparoscopic pyeloplasty in patients with secondary ureteropelvic junction obstruction after failed primary interventions. METHODS: Between August 2000 and October 2012, transperitoneal dismembered laparoscopic pyeloplasty was carried out in 13 patients with a surgical history of failed prior surgical interventions. Perioperative outcomes as well as long-term results were assessed. These outcomes were compared with those of the same procedure carried out for primary ureteropelvic junction obstruction by a single surgeon during the same study period. RESULTS: Laparoscopic transperitoneal pyeloplasty was completed successfully in all cases without converting to open surgery or requiring blood transfusion. The preoperative symptoms in 12 of 13 patients all disappeared soon after the operation. Asymptomatic severe hydronephrosis found in a 2-year-old boy reduced in size postoperatively. When comparing the primary with the secondary laparoscopic pyeloplasty carried out by the same surgeon, the mean operative time was longer (183 vs 241 min, P = 0.002), estimated blood loss was larger (33 vs 66 mL, P = 0.03) and the complication rate was higher (8.8% vs 22.2%, P = 0.01) in the secondary group. Success rates were 97.9% and 100% (P = 0.41) at a mean follow up of 25.9 and 40.0 months (P = 0.14) for the primary and secondary groups, respectively. CONCLUSIONS: Laparoscopic pyeloplasty is an excellent option for patients who failed previous surgical management. This approach provides durable long-term outcomes comparable with those of primary treatment for ureteropelvic junction obstruction.


Assuntos
Pelve Renal/cirurgia , Laparoscopia/métodos , Ureter/cirurgia , Obstrução Ureteral/cirurgia , Adolescente , Adulto , Perda Sanguínea Cirúrgica , Criança , Pré-Escolar , Feminino , Seguimentos , Humanos , Hidronefrose/diagnóstico , Hidronefrose/etiologia , Pelve Renal/anormalidades , Laparoscopia/efeitos adversos , Masculino , Pessoa de Meia-Idade , Duração da Cirurgia , Reoperação , Fatores de Tempo , Resultado do Tratamento , Ureter/anormalidades , Adulto Jovem
2.
Nephron Clin Pract ; 104(1): c28-32, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16685141

RESUMO

We administered 2.5 g of Shakuyaku-kanzo-to granule to 61 patients who had muscle cramp during hemodialysis (HD) sessions and examined its immediate effects. We selected 10 patients who wanted to take the drug at home, out of cases, for whom the drug was effective on the study described above and had them take the drug in the same way at the beginning of muscle cramp at home examined the effects. In the study during HD sessions, muscle cramp and its associated pain disappeared in 5.3 +/- 3.9 min on average in 54 out of 61 cases. In the study of patients who took the drug at home, muscle cramp disappeared within 10 min in all cases. Shakuyaku-kanzo-to is thought to be very useful for muscle cramp during HD sessions of hemodialized patients because it has immediate effects by its oral administration on the occasion of cramp. With regard to the muscle cramp, which appears at home after HD sessions, the patients can cope with it by taking the drug by themselves. This is an epoch-making therapy, for it was impossible to cope with muscle cramp except in hospitals because the therapy of muscle cramp was limited to intravenous infusion of hypertonic solutions of dextrose, mannitol, and saline during HD sessions.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Medicamentos de Ervas Chinesas/uso terapêutico , Cãibra Muscular/tratamento farmacológico , Diálise Renal/efeitos adversos , Administração Oral , Esquema de Medicação , Combinação de Medicamentos , Feminino , Glycyrrhiza , Humanos , Falência Renal Crônica/terapia , Masculino , Pessoa de Meia-Idade , Cãibra Muscular/etiologia , Cãibra Muscular/prevenção & controle , Paeonia , Resultado do Tratamento
3.
Hinyokika Kiyo ; 52(2): 155-7, 2006 Feb.
Artigo em Japonês | MEDLINE | ID: mdl-16541773

RESUMO

Urethrorectal fistula is a relatively rare disease. The most frequent cause of acquired urethrorectal fistulas is known to be iatrogenic complications, such as rectal injuries during the prostate operations. Rectal injuries are usually noticed during the operation and the majority can be repaired in situ. We report a case of late-onset urethrorectal fistula that lacked obvious rectal injury during the operation. Ischemic change or heat denaturation of rectal wall may be the potential cause of the present urethrorectal fistula.


Assuntos
Laparoscopia , Prostatectomia/efeitos adversos , Fístula Retal/etiologia , Doenças Uretrais/etiologia , Fístula Urinária/etiologia , Adenocarcinoma/cirurgia , Idoso , Humanos , Masculino , Complicações Pós-Operatórias , Neoplasias da Próstata/cirurgia
4.
Clin Calcium ; 15 Suppl 1: 15-22; discussion 22, 2005 Sep.
Artigo em Japonês | MEDLINE | ID: mdl-16272624

RESUMO

The aim of this study was to examine the therapeutic effect of hypocalcemic stimulation caused by sevelamer hydrochloride (SH) administration on adynamic bone disease (ABD). The subjects were 28 maintenance hemodialysis (HD) patients who had remained in ABD state in spite of no administration of vitamin D(3) since HD induction (15 males and 13 females;12 diabetic patients and 16 non-diabetic patients). The mean age was 61.8+/-9.5 years and the mean HD duration was 5.5+/-3.9 years. The calcium concentration in the dialysate was 3.0 mEq/L. We made the final daily dose of SH after two months the same as the first daily dose of calcium carbonate (CC) in the following manner. At first we administered only CC at breakfast and lunch and SH at supper. And for the next two weeks we administered CC at breakfast and SH at lunch and supper. And for the final two weeks we administered only SH. After that we increased the dose of SH as much as possible. We evaluated the therapeutic effect of the above treatment on ABD using intact-osteocalcin (iOC) [Teijin. Tokyo] as a marker before and 6, 12 months after the beginning of the replacement. If iOC Ievel of 30 to 70 ng/mL showed normal tumover bone (NTB), 5 cases (17.9%) changed into NTB in 6 months. 9 cases (32.1%) changed into NTB in 12 months and one case (3.6%) changed into ostitis fibrosa in 12 months. It is thought that SH is effective for the treatment of ABD but we have to be careful for ostitis fibrosa.


Assuntos
Doenças Ósseas Metabólicas/tratamento farmacológico , Carbonato de Cálcio/administração & dosagem , Poliaminas/administração & dosagem , Idoso , Biomarcadores/sangue , Doenças Ósseas Metabólicas/diagnóstico , Doenças Ósseas Metabólicas/etiologia , Esquema de Medicação , Quimioterapia Combinada , Feminino , Humanos , Hiperparatireoidismo Secundário/induzido quimicamente , Hiperparatireoidismo Secundário/prevenção & controle , Masculino , Pessoa de Meia-Idade , Osteíte Fibrosa Cística/induzido quimicamente , Osteocalcina/sangue , Poliaminas/efeitos adversos , Diálise Renal/efeitos adversos , Sevelamer , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA